Clinical trial NCT06589492: Comparison of Serum SIRT-1 and MMP-9 Levels of Patients With Bronchiectasis and Healthy Controls
Official title: A Cross-sectional Study on the Comparison of Serum SIRT-1 and MMP-9 Levels of Patients With Bronchiectasis and Healthy Controls
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bronchiectasis Adult
Keywords: Bronchiectasis
MMP-9
SIRT-1
Lead sponsor: Cumhuriyet University
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this a cross-sectinol study is to measure the levels of MMP-9 and SIRT-1 levels in patients with bronchiectasis and healthy controls. The aim is to compare the serum levels of these molecules between patients and controls.

* Is the MMP-9 level increasing or decreasing?
* Is the SIRT-1 level increasing or decreasing in patients?
* Is the disease related to age and gender? Participants will only have one 5 ml blood sample drawn when they visit the chest illness clinic. Molecule levels will be measured in this blood's serum.

The patient group participants will be scanned once with high-resolution chest CT.

Apart from this, comparisons will be made using the age and gender information of the participants.

Detailed description: In the overall study population of 60 subjects who applied to the Sivas Cumhuriyet University Faculty of Medicine Research and Practice Hospital Chest Diseases Clinic. The study population was selected regardless of age and gender. Participants selected bronchiectasis patients (n=30) who had symptoms (cough, sputum production) and had their diagnosis confirmed by a chest high-resolution CT scan within the previous year. The study excluded individuals with bronchiectasis not associated with cystic fibrosis and who had a worsening episode (according to the 2017 European Respiratory Society expert consensus criteria) (16) or had taken antibiotics during the previous four weeks. The study enrolled healthy controls (n=30) through advertisements who had acceptable chest X-ray and spirometry results and no lower airway symptoms or serious systemic disorders. The study eliminated individuals who were pregnant or nursing, as well as those with low comprehension. SIRT-1 and MMP-9 levels in the serum of the study group were determined by the ELISA method.

Eligibility criteria: Inclusion Criteria:

* Bronchiectasis patients who were symptoms (cough, sputum production)
* Individuals whose diagnosis was confirmed by a high-resolution chest CT scan taken within the previous year

Exclusion Criteria:

* Individuals with bronchiectasis associated with cystic fibrosis and who had a worsening episode
* individuals who were pregnant or nursing
* those with low comprehension
* taken antibiotics during the previous four weeks

Primary outcomes:
measure: MMP-9 and SIRT-1 levels (ng/mL) mesurment in the blood serum to compare between patient and control.
timeFrame: not measured in time frame. general (1. day)
Secondary outcomes:
Other outcomes:
Locations:
city: Si̇vas
country: Turkey
facility: Cumhuriyet University
state: Si̇vas Centre
Study officials:
References: